Products for Research Use Only
RegisterLogin

Halofuginone (lactate)

CAT: 0804-HY-N1584C-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-N1584C-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Halofuginone lactate, a Febrifugine derivative, is a competitive prolyl-tRNA synthetase inhibitor with a Ki of 18.3 nM[1][2]. Halofuginone lactate is a specific inhibitor of type-I collagen synthesis and attenuates osteoarthritis (OA) by inhibition of TGF-β activity[3][4]. Halofuginone lactate is also a potent pulmonary vasodilator by activating Kv channels and blocking voltage-gated, receptor-operated and store-operated Ca2+ channels. Halofuginone lactate has anti-malaria, anti-inflammatory, anti-cancer, anti-fibrosis effects[5].
CAS Number
82186-71-8
Product Name Alternative
RU-19110 (lactate)
UNSPSC
12352005
Hazard Statement
H301, H310, H315, H318, H330
Target
Calcium Channel; DNA/RNA Synthesis; Parasite; Sodium Channel; TGF-beta/Smad
Type
Reference compound
Related Pathways
Anti-infection; Cell Cycle/DNA Damage; Membrane Transporter/Ion Channel; Neuronal Signaling; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Cancer; Infection; Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/halofuginone-lactate.html
Concentration
10mM
Purity
98.32
Solubility
DMSO : 35 mg/mL (ultrasonic)
Smiles
OC(C(O)C)=O.O=C1C2=CC(Cl)=C(Br)C=C2N=CN1CC(C[C@H]3[C@@H](CCCN3)O)=O
Molecular Formula
C19H23BrClN3O6
Molecular Weight
504.76
Precautions
H301, H310, H315, H318, H330
References & Citations
[1]Tsuchida K, et al. Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation. Free Radic Biol Med. 2017 Feb;103:236-247.|[2]Keller TL, et al. Halofuginone and other Febrifugine derivatives inhibit prolyl-tRNA synthetase. Nat Chem Biol. 2012 Feb 12;8 (3) :311-7.|[3]Cui Z, et al. Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis. 2016 Sep;75 (9) :1714-21.|[4]Tracy L McGaha, et al. Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol. 2002 Mar;118 (3) :461-70.|[5]Pritesh P Jain, et al. Halofuginone, a Promising Drug for Treatment of Pulmonary Hypertension. Br J Pharmacol. 2021 Mar 10.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Related Products

CatalogName
HY-N1584-01Halofuginone
HY-N1584A-01Halofuginone (hydrobromide)
HY-N1584R-01Halofuginone (Standard)
HY-N1584BHalofuginone (hydrochloride)
HY-N1584AR-01Halofuginone (hydrobromide) (Standard)
HY-N1584BRHalofuginone (hydrochloride) (Standard)
HY-156882Biotin-PEG3-amide-C2-CO-Halofuginone
HY-16256Amrinone (lactate)
HY-B0519CTylosin (lactate)
HY-17395BTerbinafine (lactate)

Alternative Products

CatalogName
451693-01Halofuginone Lactate
TRC-H102480-100MGHalofuginone Lactate - MOQ
BA2045-25Halofuginone

Popular Products